SAN DIEGO, CA, June 15 /CNW/ - Nventa Biopharmaceuticals Corporation
(TSX: NVN) today announced results, recently published in the journal AIDS,
from a clinical trial to test HspE7, an investigational therapeutic vaccine
for human papillomavirus (HPV)-related diseases, on patients with high-grade
anal intraepithelial neoplasia (AIN), or dysplasia, in HIV-positive
individuals. The trial was conducted by the AIDS Malignancy Consortium at the
University of California in San Francisco and was sponsored by the U.S.
National Cancer Institute
